LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19 Patients with Lymphocytopenia Are Likely to Suffer Severe Disease Symptoms

By LabMedica International staff writers
Posted on 22 Jul 2020
Print article
Image: A scanning electron microscope image of normal circulating human blood showing red blood cells, several types of white blood cells including lymphocytes, a monocyte, a neutrophil and many small disc-shaped platelets (Photo courtesy of [U.S.] National Cancer Institute)
Image: A scanning electron microscope image of normal circulating human blood showing red blood cells, several types of white blood cells including lymphocytes, a monocyte, a neutrophil and many small disc-shaped platelets (Photo courtesy of [U.S.] National Cancer Institute)
An easily recognizable feature in blood samples may be an indicator of whether a COVID-19 patient will be likely to suffer from a severe form of the disease.

Lymphocytopenia - abnormally low levels of white blood cells - is a common systemic manifestation of many viral illnesses; in particular, other coronaviruses like Severe Acute Respiratory Syndrome coronavirus (SARS‐CoV) and Middle Eastern Respiratory Syndrome coronavirus (MERS‐CoV) have been demonstrated to cause lymphocytopenia. However, few studies have examined whether lymphocytopenia found at the time of admission to the hospital is helpful in understanding the disease course.

For this reason, investigators at the University of Texas Health Science Center at Houston (USA) studied a cohort of hospital patients diagnosed with COVID‐19 to determine whether lymphocytopenia, found at the time of admission to the hospital, was associated with disease severity and other clinical outcomes.

For this study, the investigators analyzed blood samples obtained from 57 patients from a local Houston hospital. Results revealed that lymphocyte count was lower and lymphocytopenia more frequent in patients admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to those who were not. In addition, patients with lymphocytopenia were more likely to develop an acute kidney injury (AKI), a marker of organ failure, during admission.

The investigators integrated basic demographic, clinical, and laboratory data to formulate a theory explaining the relationship between lymphocytopenia at the time of hospital admission and clinical outcomes. Furthermore, they said that their findings supported the hypothesis that lymphocytopenia could be an early, useful, and easily obtained, prognostic factor in determining the clinical course and disease severity of a patient admitted to the hospital for COVID‐19.

“Because of the uncertainty surrounding the implications of this virus, we knew there needed to be a prognostic factor that could aid hospital workers in managing COVID-19,” said senior author Dr. Ahmad Farooq, assistant professor of gastroenterology at the University of Texas Health Science Center at Houston. “In this study, we discovered evidence of a relationship between lymphocytopenia and disease severity that could really help clinicians prepare for critically ill patients. The finding of an association with AKI warrants further research. Nevertheless, it is apparent here that lymphocytopenia may serve as a prognostic marker for AKI in patients with COVID-19.”

The link between lymphocytopenia and severity of COVID-19 infection was described in the July 10, 2020, online edition of the International Journal of Laboratory Hematology.

Related Links:
University of Texas Health Science Center at Houston

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.